vs
Apellis Pharmaceuticals, Inc.（APLS）与LEE ENTERPRISES, Inc（LEE）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是LEE ENTERPRISES, Inc的1.5倍（$199.9M vs $130.1M），LEE ENTERPRISES, Inc净利率更高（-4.3% vs -29.5%，领先25.2%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -10.0%），LEE ENTERPRISES, Inc自由现金流更多（$3.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -5.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
李企业是一家上市美国传媒企业，在全美25个州运营着72份日报，同时还经营超过350份周报、分类广告刊物及各类专业刊物。公司由阿尔弗雷德·威尔逊·李于1890年创立，总部坐落于爱荷华州达文波特。
APLS vs LEE — 直观对比
营收规模更大
APLS
是对方的1.5倍
$130.1M
营收增速更快
APLS
高出4.1%
-10.0%
净利率更高
LEE
高出25.2%
-29.5%
自由现金流更多
LEE
多$18.0M
$-14.3M
两年增速更快
APLS
近两年复合增速
-5.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $130.1M |
| 净利润 | $-59.0M | $-5.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 4.0% |
| 净利率 | -29.5% | -4.3% |
| 营收同比 | -5.9% | -10.0% |
| 净利润同比 | -62.2% | 66.5% |
| 每股收益（稀释后） | $-0.40 | $-0.92 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSLEE
| Q4 25 | $199.9M | $130.1M | ||
| Q3 25 | $458.6M | $139.1M | ||
| Q2 25 | $178.5M | $141.3M | ||
| Q1 25 | $166.8M | $137.4M | ||
| Q4 24 | $212.5M | $144.6M | ||
| Q3 24 | $196.8M | $158.6M | ||
| Q2 24 | $199.7M | $150.6M | ||
| Q1 24 | $172.3M | $146.6M |
净利润APLSLEE
| Q4 25 | $-59.0M | $-5.6M | ||
| Q3 25 | $215.7M | $-6.4M | ||
| Q2 25 | $-42.2M | $-1.9M | ||
| Q1 25 | $-92.2M | $-12.5M | ||
| Q4 24 | $-36.4M | $-16.7M | ||
| Q3 24 | $-57.4M | $-10.1M | ||
| Q2 24 | $-37.7M | $-4.3M | ||
| Q1 24 | $-66.4M | $-12.2M |
营业利润率APLSLEE
| Q4 25 | -25.6% | 4.0% | ||
| Q3 25 | 48.7% | -1.0% | ||
| Q2 25 | -18.6% | 3.3% | ||
| Q1 25 | -50.0% | -3.3% | ||
| Q4 24 | -12.3% | -2.3% | ||
| Q3 24 | -24.0% | -2.3% | ||
| Q2 24 | -14.7% | 3.3% | ||
| Q1 24 | -36.0% | -3.1% |
净利率APLSLEE
| Q4 25 | -29.5% | -4.3% | ||
| Q3 25 | 47.0% | -4.6% | ||
| Q2 25 | -23.6% | -1.4% | ||
| Q1 25 | -55.3% | -9.1% | ||
| Q4 24 | -17.1% | -11.6% | ||
| Q3 24 | -29.2% | -6.4% | ||
| Q2 24 | -18.9% | -2.8% | ||
| Q1 24 | -38.5% | -8.3% |
每股收益（稀释后）APLSLEE
| Q4 25 | $-0.40 | $-0.92 | ||
| Q3 25 | $1.67 | $-1.02 | ||
| Q2 25 | $-0.33 | $-0.31 | ||
| Q1 25 | $-0.74 | $-2.07 | ||
| Q4 24 | $-0.30 | $-2.80 | ||
| Q3 24 | $-0.46 | $-1.68 | ||
| Q2 24 | $-0.30 | $-0.73 | ||
| Q1 24 | $-0.54 | $-2.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $12.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $-48.7M |
| 总资产 | $1.1B | $592.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSLEE
| Q4 25 | $466.2M | $12.6M | ||
| Q3 25 | $479.2M | $10.0M | ||
| Q2 25 | $370.0M | $14.1M | ||
| Q1 25 | $358.4M | $4.7M | ||
| Q4 24 | $411.3M | $6.1M | ||
| Q3 24 | $396.9M | $9.6M | ||
| Q2 24 | $360.1M | $13.4M | ||
| Q1 24 | $325.9M | $16.1M |
总债务APLSLEE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSLEE
| Q4 25 | $370.1M | $-48.7M | ||
| Q3 25 | $401.2M | $-43.3M | ||
| Q2 25 | $156.3M | $-40.5M | ||
| Q1 25 | $164.2M | $-38.9M | ||
| Q4 24 | $228.5M | $-26.7M | ||
| Q3 24 | $237.1M | $-9.9M | ||
| Q2 24 | $264.3M | $4.0M | ||
| Q1 24 | $266.7M | $7.9M |
总资产APLSLEE
| Q4 25 | $1.1B | $592.6M | ||
| Q3 25 | $1.1B | $601.7M | ||
| Q2 25 | $821.4M | $622.7M | ||
| Q1 25 | $807.3M | $623.9M | ||
| Q4 24 | $885.1M | $633.0M | ||
| Q3 24 | $901.9M | $649.2M | ||
| Q2 24 | $904.5M | $677.5M | ||
| Q1 24 | $831.9M | $684.8M |
负债/权益比APLSLEE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $4.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $3.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 2.9% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $1.5M |
8季度趋势，按日历期对齐
经营现金流APLSLEE
| Q4 25 | $-14.2M | $4.5M | ||
| Q3 25 | $108.5M | $-6.3M | ||
| Q2 25 | $4.4M | $8.9M | ||
| Q1 25 | $-53.4M | $-790.0K | ||
| Q4 24 | $19.4M | $-7.3M | ||
| Q3 24 | $34.1M | $-261.0K | ||
| Q2 24 | $-8.3M | $-1.9M | ||
| Q1 24 | $-133.0M | $3.2M |
自由现金流APLSLEE
| Q4 25 | $-14.3M | $3.7M | ||
| Q3 25 | $108.3M | $-8.3M | ||
| Q2 25 | $4.4M | $8.3M | ||
| Q1 25 | $-53.4M | $-2.2M | ||
| Q4 24 | $19.3M | $-8.9M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | $-8.4M | $-5.5M | ||
| Q1 24 | $-133.3M | $1.3M |
自由现金流率APLSLEE
| Q4 25 | -7.1% | 2.9% | ||
| Q3 25 | 23.6% | -6.0% | ||
| Q2 25 | 2.5% | 5.9% | ||
| Q1 25 | -32.0% | -1.6% | ||
| Q4 24 | 9.1% | -6.1% | ||
| Q3 24 | — | -1.8% | ||
| Q2 24 | -4.2% | -3.6% | ||
| Q1 24 | -77.3% | 0.9% |
资本支出强度APLSLEE
| Q4 25 | 0.1% | 0.6% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 2.4% | ||
| Q1 24 | 0.2% | 1.3% |
现金转化率APLSLEE
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
LEE
| Advertising And Marketing Services | $60.0M | 46% |
| Subscription And Circulation | $57.7M | 44% |
| Other | $12.4M | 10% |
